Baidu
map

Clin Cancer Res:αB-crystallin有望成为乳腺癌脑转移的生物标志物

2013-11-27 MedSci MedSci原创

三阴性乳腺癌是一类预后不佳,易于脑转移的乳腺癌病理类型。在人群队列研究中发现,三阴性乳腺癌组织中αB-crystallin呈现高表达。在体外模型中研究也发现,高倾袭细胞株TNBC也高表达αB-crystallin,如果稳定过表达αB-crystallin,能促进TNBC细胞粘附于脑微动脉内皮细胞,并有助于TNBC透过血脑屏障。反之,如果抑制αB-crystallin表达,则能抑制TNBC的倾袭作用

三阴性乳腺癌是一类预后不佳,易于脑转移的乳腺癌病理类型。在人群队列研究中发现,三阴性乳腺癌组织中αB-crystallin呈现高表达。在体外模型中研究也发现,高倾袭细胞株TNBC也高表达αB-crystallin,如果稳定过表达αB-crystallin,能促进TNBC细胞粘附于脑微动脉内皮细胞,并有助于TNBC透过血脑屏障。反之,如果抑制αB-crystallin表达,则能抑制TNBC的倾袭作用。
因此,研究者认为,αB-crystallin有望成为三阴性乳腺癌脑转移的重要调节物,也可能成为新型的脑转移预测标志物。

原始出处:
Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton EP, Blackwell K, Geradts J, Ewend M, Carey LA, Shusta EV, Anders CK, Cryns VL.αB-crystallin: a Novel Regulator of Breast Cancer Metastasis to the Brain. Clin Cancer Res. 2013 Oct 16.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840781, encodeId=e46d1840e818a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 08 16:10:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328848, encodeId=92841328848cd, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560510, encodeId=919215605108f, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566519, encodeId=37021566519d2, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840781, encodeId=e46d1840e818a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 08 16:10:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328848, encodeId=92841328848cd, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560510, encodeId=919215605108f, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566519, encodeId=37021566519d2, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
    2013-11-29 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840781, encodeId=e46d1840e818a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 08 16:10:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328848, encodeId=92841328848cd, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560510, encodeId=919215605108f, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566519, encodeId=37021566519d2, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840781, encodeId=e46d1840e818a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 08 16:10:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328848, encodeId=92841328848cd, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560510, encodeId=919215605108f, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566519, encodeId=37021566519d2, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Fri Nov 29 01:10:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]

相关资讯

Clin Cancer Res:ER阳性、HER2阴性的转移性乳腺癌(MBC)患者可从拉帕替尼获益?

拉帕替尼是EGFR和HER2双重抑制剂,但尚未被批准用于治疗非HER2扩增的转移性乳腺癌(metastaticbreast cancer, MBC)。EG30008是一项比较来曲唑加拉帕替尼和来曲唑加安慰剂的疗效的III临床试验,其证实拉帕替尼能够显著改善HER2扩增、非HER2阴性的绝经后的转移性乳腺癌妇女的预后。据此提出假设 :HER2阴性队列中激素受体表达水平是否与治疗获益有关。该项研究近期

ESMO 2013:T-DM1可以使晚期HER2阳性乳腺癌二线治疗获益(TH3RESA研究)

III期TH3RESA试验结果显示,“ado-trastuzumab emtansine”(Kadcyla,以前称作T-DM1)能够提高既往接受过2种或2种以上的HER2靶向治疗(包括曲妥单抗和拉帕替尼)的晚期 HER2阳性乳腺癌患者的无进展生存期。研究结果公布于阿姆斯特丹举办的2013年欧洲癌症大会上。这些新数据扩大了该药物最初在EMILIA中的使用人群。根据EMILIA研究,FDA批

检测乳腺癌基因或带来激烈预防手段,如乳腺切除术的增加

  在美国人类遗传学协会年会上,与会科学家爆发了一场激烈讨论,辩论围绕着一个热点问题:何时人们能足够了解稀有癌症风险基因,开始对有癌症家族病史的人进行常规检测。因为许多患者检测基因后,进行乳腺切除手术,这类手术也称为Risk-reducing surgery,但它的疗效利弊仍然存在争议。   争论的一方是由遗传学家Mary-Claire King领衔的研究小组,他们发现了首个遗传

JCO:拉帕替尼用于乳腺癌的不良反应与年龄及治疗效果的相关性(NeoALLTO研究)

在应用拉帕替尼和/或曲妥单抗最优化新辅助治疗(NeoALLTO)乳腺癌的III期临床试验中,研究者评估了应用拉帕替尼后出现皮疹、腹泻和肝功损害的情况,以及这些不良反应与年龄和病理完全缓解(pCR)的关系。研究结果发表于近期的《临床肿瘤学》(JCO)杂志上研究详情:HER2阳性的早期乳腺癌患者被随机分配到接受拉帕替尼治疗组(A组)、接受曲妥单抗治疗组(B组)或接受拉帕替尼和曲妥单抗联合治疗组(C组)

Genome Biol:乳腺癌中DNA甲基化和拷贝数改变调控miRNA异常表达

   挪威奥斯陆大学等机构的研究人员对乳腺癌队列人群进行分析,揭示了DNA甲基化和拷贝数改变对microRNA表达的影响,从而为乳腺癌中miRNA失调背后的机制提供了新证据。这项研究成果于11月20日发表在Genome Biology上。   microRNA(miRNA)是一类小的非编码RNA分子,它通过控制mRNA稳定性和翻译而在转录后水平上调控基因表达。之前的研究

Oncogene:致命乳腺癌复发的潜在原因

北卡罗来纳大学(UNC)医学院的研究者,发现了为什么一些最具侵略性和致命性的乳腺癌细胞能够抵抗化疗,他们研发了克服这种抵抗力的方法。药理学系的助理教授Adriana S. Beltran博士发现,Engrailed 1蛋白在基底细胞样癌中过表达,她在实验室设计了一个氨基酸链来关闭这个蛋白,杀死基底细胞样肿瘤。 这项研究发表在最近的Oncogene杂志上,Beltran是本文的第一作者,她称:“基

Baidu
map
Baidu
map
Baidu
map